<DOC>
	<DOCNO>NCT01379391</DOCNO>
	<brief_summary>Factors influence platelet engraftment allogeneic hematopoietic stem cell transplantation ( Allo-HSCT ) include previous chemotherapy course , condition regimen , HLA compatibility , source stem cell , CD34+ cell count , infection virus/bacteria/fungal , graft-versus-host disease ( GVHD ) , etc . Large-scaled clinical trial demonstrate platelet count 20G/L 14 day transplantation predictive factor delay platelet engraftment , lead increase platelet infusion requirement high risk bleeding . Multivariable survival analysis indicate delayed platelet engraftment Allo-HSCT independent predictive factor transplantation relate mortality ( TRM ) . But effective treatment approach delay platelet recovery Allo-HSCT still lack . Recombinant human thrombopoietin ( rHuTPO ) fully modify recombinant human thrombopoietin accurately express mammalian cell . The rHuTPO agent manufacture 3Bio Pharmaceutical Limited Liability Company ( LLC ) Shenyang approve State Food Drug Administration ( SFDA ) China 2005 first rHuTPO agent available globally . RHuTPO approve immune thrombocytopenia chemotherapy-related thrombocytopenia China . Animal experiment show TPO-mobilizing stem cell could promote platelet engraftment Allo-HSCT mouse . As efficacy safety TPO platelet engraftment Allo-HSCT , 's marginally addressed clinical trial . Based preliminary research result , investigator design phase IV , open-label , prospective , multicenter Study efficacy safety recombinant human thrombopoietin injection ( rHuTPO , TPIAO ) platelet engraftment Allo-HSCT China .</brief_summary>
	<brief_title>Efficacy Safety rHuTPO Platelet Engraftment After Allo-HSCT</brief_title>
	<detailed_description />
	<criteria>1 . Ages : 18 year 65 year . 2 . Patients receive myeloablative allogeneic hematopoietic stem cell transplantation relate nonrelated , HLA compatible incompatible donor . History control concurrent control use . 3 . The platelet count low 20G/L +14d posttransplant . 4 . The informed consent form sign . 5 . The following exclusion criterion exclude . 1 . Patients receive nonmyeloablative hematopoietic stem cell transplantation . 2 . Patients severe cardiocerebral disease grade III A YHA cardiac function past history coronary heart disease , cerebral thrombosis , cerebral arteriosclerosis , etc . 3 . Patients severe hepatic renal dysfunction 5 time upper limit normal range ( ULN ) serum ALT AST level , 5 time upper limit normal range ( ULN ) serum TBIL level le 40 % normal prothrombin time activity ( PTA ) ; 3 time ULN serum Cr . 4 . Patients history deep vein thrombosis within 8 week enrollment . 5 . Patients hepatic obstructive venous disease without recovery within 2 week enrollment . 6 . Patients thrombotic microangiopathy without recovery within 2 week enrollment . 7 . Patients capillary leaking syndrome without recovery within 2 week enrollment . 8 . Patients condition consider unsuitable study . 9 . Patients hypercoagulopathy condition two criterion : INR low 0.82 , APTT low low limit normal value ( 23 second ) PT low low limit normal value ( 10 second ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Platelet Engraftment</keyword>
	<keyword>TPO</keyword>
</DOC>